PinnyPeptide

ARA-290 (Cibinetide) vs KPV

Side-by-side comparison: effects, dosing ranges, side effects, regulatory status, and reconstitution.

Peptide A

ARA-290 (Cibinetide)

Healing & Recovery

Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects.

Peptide B

KPV

Healing & Recovery

Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone.

Typical vial

8 mg

Typical dose

2,000-8,000 mcg

Half-life

~2 minutes (plasma); longer functional duration via receptor binding

FDA status

Not FDA approved. In clinical development by Araim Pharmaceu…

Typical vial

5 mg

Typical dose

200-500 mcg

Half-life

~15-30 minutes (short half-life typical of small peptides)

FDA status

Not FDA approved for human use.

ARA-290 (Cibinetide) effects

  • Activates the innate repair receptor (IRR / EpoR-βcR heterodimer)
  • Reduces tissue inflammation in injury models
  • Promotes axonal regeneration in small-fiber neuropathy
  • Does NOT raise hemoglobin or platelet count
  • Tissue-protective in ischemia-reperfusion models

KPV effects

  • Potent anti-inflammatory action via NF-kB inhibition
  • Reduces intestinal inflammation when taken orally
  • Exhibits antimicrobial activity against bacteria and fungi
  • Modulates pro-inflammatory cytokine release
  • Supports gut barrier integrity

ARA-290 (Cibinetide) side effects

  • Generally well-tolerated in clinical trials
  • Injection-site reactions (mild)
  • No erythropoietic effects (deliberate design)
  • Long-term safety with chronic dosing still being characterized

KPV side effects

  • Generally well tolerated at studied doses
  • Mild gastrointestinal discomfort at higher doses
  • Temporary skin flushing (rare)

ARA-290 (Cibinetide) dosing ranges

Small-fiber neuropathy / nerve healing

2-8 mg · Once daily (SubQ) · 4-12 weeks per cycle

General tissue protection research

1-4 mg · Daily or alternate-day · Per research protocol

KPV dosing ranges

Gut inflammation support

200-500 mcg · Once or twice daily (oral or SubQ) · 4-8 weeks

Systemic anti-inflammatory

200-500 mcg · Once daily (SubQ) · 4-6 weeks

Full ARA-290 (Cibinetide) guide → Full KPV guide →

ARA-290 (Cibinetide) vs KPV — common questions

What is the difference between ARA-290 (Cibinetide) and KPV?

ARA-290 (Cibinetide): Tissue-protective helix-B fragment of erythropoietin — without the red-blood-cell effects. Typical dose 2,000-8,000 mcg. KPV: Anti-inflammatory tripeptide derived from alpha-melanocyte stimulating hormone. Typical dose 200-500 mcg. Both fall under the Healing & Recovery category.

Can you stack ARA-290 (Cibinetide) and KPV?

Stacking ARA-290 (Cibinetide) with KPV is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Which is dosed more frequently, ARA-290 (Cibinetide) or KPV?

ARA-290 (Cibinetide) is typically dosed: Once daily (SubQ) for Small-fiber neuropathy / nerve healing; Daily or alternate-day for General tissue protection research. KPV is typically dosed: Once or twice daily (oral or SubQ) for Gut inflammation support; Once daily (SubQ) for Systemic anti-inflammatory.

Are ARA-290 (Cibinetide) and KPV FDA approved?

ARA-290 (Cibinetide): Not FDA approved. In clinical development by Araim Pharmaceuticals. Granted orphan drug designation for sarcoidosis-related conditions. KPV: Not FDA approved for human use.

Related peptide comparisons

ara-290 vs b7-33ara-290 vs bpc-157ara-290 vs tb-500ara-290 vs tb-500-frag-17-23ara-290 vs vipbpc-157 vs kpv

Tracking either of these?

Log doses, automate injection site rotation, and never lose track of where you last pinned. Free forever.

Get Started Free